Bibliography
- Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
- Simao ANC, Lozovoy MAB, Simao TNC, Immunological and biochemical biomarkers in patients with metabolic syndrome and involvement of oxidative and nitroactive stress. Braz J Med Biol Res 2011;44:707-12
- Lozovoy MAB, Simao ANC, da Silva E, Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011;20:1356-64
- Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70
- Ouchi N, Kihara S, Arita Y, Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301
- Simao ANC, Lozovoy MAB, Simao TNC, Adiponectinemia is associated with uricemia but not with proinflammatory status in women with metabolic syndrome. J Nutr Metab 2011;2012(2012):7
- Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 2006;155:745-50
- Zhu W, Cheng KKY, Vanhoutte PM, Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 2008;114:361-74
- Simao ANC, Lozovoy MAB, Bahls LD, Blood pressure decrease with ingestion of a soy product (kinako) or fish oil in women with metabolic syndrome: role of adiponectin and nitric oxide. Br J Nutr; In press
- Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adypocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563-8
- Ohashi K, Kihara S, Ouchi N, Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006;47:1108-16
- Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91(Suppl):258S-61S
- Ouchi N, Ohishi M, Kihara S, Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003;42:231-4
- Hermann M, Flammer A, Luscher TF. Nitric oxide in hypertension. J Clin Hypertens 2006;8(12 Suppl):17-29
- Skalicky J, Muzakova V, Kandar R, Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med 2008;46:499-505
- Yamaguchi Y, Yoshikawa N, Kagota S. Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. Nitric Oxide 2006;15:380-6
- Nakagawa T, Hu H, Zharikov S, A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625-31
- Niskanen LK, Laaksonen DE, Nyyssonen K, Uric acid level as a risk for cardiovascular and all-mortality in middle-age men: a prospective cohort study. Arch Intern Med 2004;164:1546-51
- Simao ANC, Dichi JB, Barbosa DS, Influence of uric acid and gamma-glutamyltransferase on total antioxidant capacity and oxidative stress in patients with metabolic syndrome. Nutrition 2008;24:675-81
- Simao ANC, Dichi I. Role of uric acid in metabolic syndrome. In: Castillo SE, Maldonado EW, editors. Uric Acid: Biology, Functions and Diseases. Nova Science Publishers; New York: 2012; In press
- Munzel T. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010;31:2741-8